Tumor vaccine - customized "immune training camp" to target cancer
For cancer patients and high-risk groups, traditional treatment and screening methods often face the limitation of "passive defense". The tumor vaccine technology launched by Guangzhou R&F Hospital Tumor Center takes "actively stimulating immune memory and accurately preventing recurrence and metastasis" as the core, providing international patients (especially in Southeast Asia and the Middle East) with a full-cycle solution from cancer prevention to radical cure. This technology trains the immune system to recognize the characteristics of cancer cells. Clinical data in 2024 showed that the 5-year recurrence rate of postoperative patients was reduced to 12% (traditional treatment is 35%), and the prevention effectiveness of Southeast Asian nasopharyngeal carcinoma and Middle Eastern breast cancer was 89% and 76% respectively.
What is a tumor vaccine?
Tumor vaccines are a biotechnology that "trains the immune system to recognize cancer cells" and are divided into two categories:
Preventive vaccines: targeting carcinogenic viruses (such as HPV, hepatitis B virus), blocking infection through early vaccination to prevent cervical cancer, liver cancer, etc.;
Therapeutic vaccines: for people who have already had cancer, extracting patients' tumor-specific antigens (such as mutant proteins) to make personalized vaccines, activating T cells to accurately hunt down cancer cells, and even clearing hidden metastatic lesions.
Mechanism of action: The vaccine transmits the characteristic "markers" of cancer cells to the immune system, which is equivalent to providing a "wanted order" for immune cells, allowing them to patrol the body for a long time and destroy recurrent cancer cells at any time.
To assess whether you are suitable for cancer vaccines, please consult a doctor online
Which population is suitable for tumor vaccines?
Vaccine Type | Applicable Scenarios | Typical Cases |
Preventive Vaccines | Healthy people prevent virus-related cancers | HPV vaccine prevents cervical cancer; Hepatitis B vaccine prevents liver cancer |
Personalized Therapeutic Vaccines | 1. Postoperative recurrence prevention (e.g., lung cancer, colorectal cancer) 2. Combination immunotherapy for advanced tumors 3. Familial high-risk populations for hereditary cancer (e.g., BRCA mutations) | Postoperative colorectal cancer recurrence prevention vaccine; Melanoma neoantigen vaccine |
Therapeutic vaccines VS traditional treatments have significant advantages
Treatment Methods | Action Targets | Sustainability of Efficacy | Side Effects | Applicable Stages |
Chemotherapy/Radiotherapy | Indiscriminate killing of cancer cells | Short-term control | Hair loss, organ damage | Middle and late-stage cancer |
Immune Checkpoint Inhibitors | Relieve T-cell suppression | Months – years | Immune-related inflammation | Patients with positive specific biomarkers |
Tumor Vaccines | Systemic immune monitoring | Forming long-term or lifelong immune memory | Low fever (<20% incidence), redness/swelling at injection site | Prevention, early/middle stages, postoperative recurrence prevention |
To assess whether you are suitable for cancer vaccines, please consult a doctor online
Why choose Guangzhou R&F Hospital?
International synchronization of technology: Unlike some hospitals in Southeast Asia and the Middle East that only provide standardized vaccines, our hospital uses:
○ Neoantigen vaccine: customized based on the patient's tumor gene mutation, with a target accuracy of over 90%;
○ Dendritic cell vaccine: Tumor antigens are loaded in vitro, and T cell activity is greatly improved after infusion.
Multi-antigen composite vaccine: Nasopharyngeal carcinoma vaccine contains EB virus LMP1 + regional high-incidence mutation antigens; breast cancer vaccine integrates GCC gene mutation + Middle East-specific SNP sites
Both prevention and treatment are important:
○ Provide HPV, hepatitis B vaccine and other internationally certified prevention programs for healthy people;
○ Customize anti-recurrence vaccines for postoperative patients, and the 5-year recurrence rate is reduced by 40%-60%.
Combined treatment to enhance efficacy: Vaccines combined with PD-1 inhibitors can transform "cold tumors" into "hot tumors", increasing the efficacy by 3 times.
Mobile vaccine factory: complete the process from biopsy to vaccine preparation within 72 hours
More suitable for international patients:
○ Halal-certified mRNA lipid carrier (without porcine ingredients)
○ Buddhist vaccine contains plant-derived adjuvant
○ Female privacy protection injection service
Guangzhou R&F Hospital Cancer Center has created a three-level defense system of "treatment-prevention-monitoring":
☑ Treatment vaccine: start within 1 week after surgery to accurately remove residual cancer cells
☑ Prevention vaccine: for high-risk groups, strengthen vaccination once a year
☑ Immune monitoring: analyze T cell activity through AI to warn of recurrence risk
To assess whether you are suitable for cancer vaccines, please consult a doctor online
Guangzhou R&F Hospital International Cancer Center Real patient case: lifeline ignited by tumor vaccine
Treatment case:
Name: Mohammed (Saudi Arabia, 34 years old, advanced melanoma)
Condition: BRAF V600E mutation, PD-1 treatment resistance
Treatment plan: personalized new antigen vaccine + low-dose IL-2
Results:
✓ Tumor shrunk by 52% after 8 weeks
✓ Distal immune effect appeared (lesions at non-injected sites disappeared)
✓ Complete the pilgrimage to Mecca during treatment
Prevention cases:
Name: Chen family (Vietnam, 5 generations of high incidence of nasopharyngeal cancer)
Intervention measures: familial EB virus antigen vaccine + annual booster vaccination
Results:
✓ 0% incidence rate in the third generation of vaccinees in 10 years (68% incidence rate in the previous generation at the same time)
✓ 99% reduction in saliva EB virus load of family members
“We finally broke the genetic curse.” - Chen Wenyong, the eldest son of the fifth generation of the family
Other tumor vaccination cases
Case 1: Cervical cancer prevention (Malaysia, 24 years old)
HPV16/18 positive with cervical intraepithelial neoplasia (CIN III), reexamined 6 months after vaccination with the nine-valent HPV vaccine, the lesions reversed, and HPV turned negative.
Case 2: Prevention of recurrence after colorectal cancer surgery (UAE, 58 years old)
After stage III colorectal cancer surgery, received personalized new antigen vaccine treatment, no recurrence within 2 years, and circulating tumor DNA (ctDNA) remained negative.
Case 3: Advanced lung cancer (Indonesia, 45 years old)
EGFR wild-type lung adenocarcinoma, PD-1 monotherapy is ineffective. After combined with tumor vaccine, the tumor shrank by 50% in 3 months, and peripheral blood anti-cancer T cells expanded 10 times.
For more patient stories, please click
With vaccines as a shield, we build a lifelong immune barrier for life. Let a strong immunity become a genetic gift, and we can rewrite the fate of family cancer.
Guangzhou R&F Hospital Cancer Center opens the era of "survival without chemotherapy" for cancer patients and wins a lasting victory for life. If you or your family are facing the dilemma of cancer treatment, please contact Guangzhou R&F Hospital Cancer Center. We provide multilingual medical record consultation, contact us immediately to obtain an assessment of treatment eligibility.
Contact us:
email: rfcancercenter@gmail.com |
whatsapp: +86 18565157271
